ReviewMolecular therapy. Oncology2025
Targeting BCMA in multiple myeloma: A comprehensive review of immunotherapeutic strategies and clinical outcomes.
Review in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.American journal of hematology · 2026Article
- Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy.iScience · 2026Review
- Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antibody therapeutics · 2026Review
- Burden of infections and preventive strategies in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies.Frontiers in oncology · 2026Article
- Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma.Theranostics · 2026Article
- Engineering TCR-directed T-cells for the treatment of multiple myeloma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, highlighting an urgent need for novel therapeutic strategies. B cell maturation antigen (BCMA), predominantly expressed on mature B lymphocytes, plays a critical role in B cell activation and maturation. Growing evidence underscores the involvement of BCMA in tumor growth, metastasis, and cancer stemness, establishing it as a promising therapeutic target. This review provides a comprehensive overview of BCMA-targeted immunotherapeutic strategies in MM, including chimeric antigen receptor (CAR) T cell therapy, bispecific antibodies, and antibody-drug conjugates (ADCs). While these therapies have shown remarkable clinical efficacy, challenges such as antigen escape, on-target/off-tumor toxicity, and treatment resistance persist. Future directions include the development of next-generation CAR T cells, combination therapies with other immunomodulatory agents, and innovative strategies to overcome resistance mechanisms. We also discuss the clinical outcomes, limitations, and transformative potential of these novel therapies in the management of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.